Clinicopathological relevance of BRAF mutations in human cancer
about
Synchronous triple colorectal carcinoma: a case report and review of literatureToward a Molecular Classification of Colorectal Cancer: The Role of BRAFFuture directions for monitoring treatment response in colorectal cancerBRAF Mutation in Hairy Cell LeukemiaSomatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samplesLack of BRAF-V600E Mutation in Papillary Tumor of the Pineal Region.Synchronous colorectal cancer: clinical, pathological and molecular implications.The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.Hairy cell leukemia in kidney transplantation: lesson from a rare disorder.The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.Role of the BrafV637E mutation in hepatocarcinogenesis induced by treatment with diethylnitrosamine in neonatal B6C3F1 mice.BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cellsGermline large genomic alterations on 7q in patients with multiple primary cancers.Genetics and epigenetics of sporadic thyroid cancer.The utility of immunohistochemistry for providing genetic information on tumors.Pathology of serrated colorectal lesions.Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms.The Emerging Molecular Foundations of Pediatric Brain Tumors.Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.Novel FAM134B mutations and their clinicopathological significance in colorectal cancer.Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.Functional variomics and network perturbation: connecting genotype to phenotype in cancer.The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.An extremely rare case of concurrent BRAF V600E mutation driven hairy cell leukemia and melanoma: case report and review of literature.Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers.Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer.The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity.Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.BRAF V600E mutation-specific immunohistochemistry is a rare finding in dendritic cell- and histiocyte-derived tumors.Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer
P2860
Q26783392-684C19CF-21D1-4B9D-A148-B714A78C452DQ26827212-09354B8D-E6BA-45A2-A203-B5109CE86688Q27008428-A4C65CCD-79F0-4AD6-806F-154F959B967EQ27014016-21CAD5AE-0B7D-44FC-ACAE-E44CC41C02A4Q28070226-540E7958-E707-4D25-978C-4D5C9063029BQ30977659-E9D83145-94CA-42F7-8FAF-8390D9211AE8Q33735244-F5687606-FC3C-4A16-A29C-C751942A9D3CQ33912171-9C59613C-E2AD-484F-9C70-81860C37253EQ34520869-B9B5D9B5-15E3-4CDB-BD8C-DAFA4A2D0D52Q36006605-239690A6-560A-4DFB-AAFA-576AB5FF9AE8Q37113464-2BEE9728-49CE-40A5-BC38-73097C12025CQ37308973-30F1A38E-DEA1-4E7A-AD75-CEF9D1BD9462Q37558112-C90A0894-8071-4E16-A622-CC3F46040F8CQ37565246-DF4C4820-E0C3-407A-8823-F28E44541A4EQ37615396-A60965F6-23A3-4719-982B-6B74BF93AF1EQ38128097-13EE5C97-EAA2-4EE0-91F8-E1C08E3DEB5BQ38142818-2BF21073-E026-4E6E-88AD-0E69973F4856Q38190348-1A81CB5A-CDD6-4F1C-A22D-93C90FC8F5E4Q38377890-3E38C951-5E87-4DEC-BC15-4D18A9BC6D99Q38421001-EF47E82E-29F2-43D0-81BD-7586C03C7D54Q38555962-D1437957-85F2-437E-A886-7420BE8C86C3Q38718527-241BDAD3-2B36-4067-AA68-9F74AAB97F6AQ38740129-BACB1E31-B986-4C5F-8316-42CF834B9DB2Q38838631-7DCE2B19-FD27-468E-9E0D-2D6A6EEEF264Q39022580-B1CED0AD-D9CC-458E-A261-CF18FD75A520Q39201399-71020BBF-2EDC-4658-9B8F-856EDD290850Q40416322-FFE799E9-373D-4B40-822C-A5003F06422EQ41241610-DAD2201F-07A7-4E9F-9583-69D9A81385D9Q42373884-818363E3-9047-4D76-B37D-4B55506930CFQ42625139-8FCB0E48-4228-4E8B-A22D-8DAB6FED0B85Q47376223-576BCB85-57E0-4BF9-8031-F8AEA001C992Q47614611-615972AD-2836-4358-BD4F-04A2851831EEQ52640415-5B50FF8C-F7F7-4F9C-89C8-26326C3637BAQ52684450-CD55F707-EC8D-49D6-84AA-BE89CF72994EQ53177096-4CCDA530-A4D0-41DC-A3F8-7CBA4F308FA5Q54266014-C0F30275-B82D-4BC2-8207-250C94D44FDFQ54320679-D7C5979C-8556-43E2-BC29-4A899767C5DFQ55042787-B7FD987C-4F16-4832-A853-1DAAF87AE6B8Q58573219-BF885770-0181-424F-82EC-F2E6198311F9
P2860
Clinicopathological relevance of BRAF mutations in human cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinicopathological relevance of BRAF mutations in human cancer
@ast
Clinicopathological relevance of BRAF mutations in human cancer
@en
Clinicopathological relevance of BRAF mutations in human cancer
@nl
type
label
Clinicopathological relevance of BRAF mutations in human cancer
@ast
Clinicopathological relevance of BRAF mutations in human cancer
@en
Clinicopathological relevance of BRAF mutations in human cancer
@nl
prefLabel
Clinicopathological relevance of BRAF mutations in human cancer
@ast
Clinicopathological relevance of BRAF mutations in human cancer
@en
Clinicopathological relevance of BRAF mutations in human cancer
@nl
P3181
P1433
P1476
Clinicopathological relevance of BRAF mutations in human cancer
@en
P2093
Robert Anthony Smith
Sahar Pakneshan
P304
P3181
P356
10.1097/PAT.0B013E328360B61D
P407
P577
2013-06-01T00:00:00Z